The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community collaborates in exceptional ways an
In this latest podcast, pharmaphorum spoke to Andrew Meade, life sciences lead UK and Ireland at Accenture, about the trends that emerged in this year’s Q1 results season.
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte
